Şunu aradınız:: oncology (Hollandaca - İngilizce)

freasenius kabi oncology plc.
fresenius kabi oncology plc.

2) – addendum on paediatric oncology.
choice of non-

eastern cooperative oncology group-performance status
ecog - performance status

eastern cooperative oncology group-performance status verergerd
eastern cooperative oncology group performance status worsened

baxter oncology gmbh kantstraße 2 d-33790 halle duitsland
baxter oncology gmbh kantstraße 2 d-33790 halle germany

baxter oncology gmbh kantstraße 2 d-33790, halle duitsland
baxter oncology gmbh, kantstrasse 2, d-33790 halle, germany.

baxter oncology gmbh kantstrasse 2 33790 halle/westfalen duitsland
baxter oncology gmbh kantstrasse 2 33790 halle/westfalen germany

naam en adres van de fabrikant verantwoordelijk voor vrijgifte fresenius kabi oncology plc
name and address of the manufacturer(s) responsible for batch release fresenius kabi oncology plc

baxter oncology gmbh, kantstraße 2, d-33790, halle, duitsland
baxter oncology gmbh, kantstrasse 2, d-33790 halle, germany. for any information about this medicinal product, please contact the local representative of the marketing authorisation holder.

ldh: lactate dehydrogenase, ecog ps: eastern oncology group performance status
ldh: lactate dehydrogenase, ecog ps: eastern cooperative oncology group performance status

voor msd oncology is mensen helpen kanker te bestrijden onze passie en het ondersteunen van de toegankelijkheid tot onze kankermedicijnen onze verplichting.
at msd oncology, helping people fight cancer is our passion and supporting accessibility to our cancer medicines is our commitment.

alleen patiënten met een eastern cooperative oncology group (ecog) performance status van 0 of 1 kwamen in aanmerking.
only patients with eastern cooperative oncology group (ecog) performance status 0 or 1 were eligible.

meer dan 99% van de patiënten had een ecog (eastern cooperative oncology group) performance status van 0 of 1.
over 99% of patients had an ecog (eastern cooperative oncology group) performance status of 0 or 1.

baxter oncology gmbh kantstrasse 2 33790 halle/westfalen duitsland of catalent uk packaging limited sedge close headway great oakley corby northamptonshire nn18 8hs verenigd koninkrijk
manufacturer baxter oncology gmbh kantstrasse 2 33790 halle/westfalen germany

recombinante hematopoëtische groeifactoren kunnen worden gebruikt overeenkomstig de instellingsrichtlijnen of de richtlijnen van de european society for medical oncology (esmo).
recombinant hematopoietic growth factors may be used according to institutional or european society for medical oncology (esmo) guidelines.

de eastern cooperative oncology group (ecog) performance status was vergelijkbaar voor beide groepen, net als het aantal en type eerdere behandelingen.
the ecog performance status was comparable between both groups, as was the number and type of prior therapies.

de international classification of diseases for oncology (icd-o) is een op oncologie toegespitste uitbreiding van de international statistical classification of diseases and related health problems.
the international classification of diseases for oncology (icd-o) is a domain-specific extension of the international statistical classification of diseases and related health problems for tumor diseases.

in beide armen was de eastern cooperative oncology group (ecog)-performance status voor 76% van de patiënten 0, voor 24% van de patiënten 1.
the eastern cooperative oncology group (ecog) performance status was 0 for 76% of patients, and 1 for 24% of patients in both arms.

aa=zytiga; bpi=brief pain inventory; bi=betrouwbaarheidsinterval; ecog=eastern cooperative oncology group performance score; hr=hazard ratio; ne=niet evalueerbaar
aa = zytiga; bpi = brief pain inventory; c.i. = confidence interval; ecog = eastern cooperative oncology group performance score; hr = hazard ratio; ne = not evaluable